XZP-5610 / Sihuan Pharmaceutical - LARVOL DELTA

Dose Prediction and Pharmacokinetic Simulation of XZP-5610, a Small Molecule for NASH Therapy, Using Allometric Scaling and Physiologically Based Pharmacokinetic Models. (PubMed, Pharmaceuticals (Basel)) - "The PK profiles and parameters of XZP-5610, predicted using the PBPK model, demonstrated good consistency with the clinical data. By using allometric scaling and PBPK models, the doses, PK profile, and especially the liver concentrations were successfully predicted in the FIH study."

Journal • PK/PD data • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis